Avastin will continue to be available as an approved treatment for certain kinds of colon, lung, kidney and brain cancers.
FDA Commissioner Margaret A. Hamburg, MD, said a review of the literature showed there is no evidence Avastin will delay tumor growth, help patients live longer or improve their quality of life. She said the unproven benefit of Avastin for breast cancer does not justify the “potentially life-threatening side effects,” according to the release.
Avastin’s risks include severe high blood pressure; bleeding and hemorrhaging; heart attack or heart failure; and perforations in different parts of the body such as the nose, stomach and intestines, according to the release.
Related Articles on Hospital Oncology:
Report: Prostate Cancer Drug Market to Reach $10.1B in 2020
Breast Cancer Therapy Market Projected to Increase Marginally Over Next Decade
Former Radiology Technician Allegedly Falsified Unread Mammograms as Negative
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
